Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lutetium-177 labeled humanized monoclonal antibody targeting leucine rich repeat containing 15
- Development stage
- Discontinued
- Lead developer
- Radiopharm Theranostics, Ltd
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RAD-502 is a radiolabeled therapeutic monoclonal antibody designed to target leucine-rich repeat-containing protein 15 (LRRC15), a cell surface protein overexpressed in various tumors. The drug consists of a humanized monoclonal antibody conjugated with the radioisotope lutetium-177, enabling targeted radioimmunotherapy. By binding to LRRC15 on tumor cells, RAD-502 delivers localized radiation intended to halt tumor progression and prolong survival. It was initially developed by Radiopharm Theranostics for the treatment of neoplasms such as osteosarcoma and other cancers but has been discontinued in preclinical development[2][3][4].
- Other names
- Lutetium-177 labeled humanized monoclonal antibody targeting LRRC15Lutetium177 labeled humanized monoclonal antibody targeting LRRC15Lutetium 177 labeled humanized monoclonal antibody targeting LRRC15
02
Targets
LRRC15 (Leucine-rich repeat-containing protein 15)
Beyond the preview
Go deeper on Lutetium-177 labeled humanized monoclonal antibody targeting leucine rich repeat containing 15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lutetium-177 labeled humanized monoclonal antibody targeting leucine rich repeat containing 15.